Evidence map›Paper›PMID 28594851›Full record

ArticlePloS one2017

Serum N-glycome characterization and anti-carbohydrate antibody profiling in oral squamous cell carcinoma patients.

Shih-Yun Guu, Tsung-Hsien Lin, Su-Chieh Chang, Rei-Jing Wang, Ling-Yi Hung, Po-Jan Fang, Wei-Chien Tang, Peiwen Yu, Chuan-Fa Chang

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Serum antibody screening using glycan arrays.Chemical Society reviews · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. CD16a with oligomannose-typeThe Journal of biological chemistry · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Shih-Yun GuuDepartment of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Tsung-Hsien LinDepartment of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Su-Chieh ChangDepartment of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Rei-Jing WangDepartment of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Ling-Yi HungOBI Pharma, Inc., Taipei, Taiwan, R.O.C.
Po-Jan FangOBI Pharma, Inc., Taipei, Taiwan, R.O.C.
Wei-Chien TangOBI Pharma, Inc., Taipei, Taiwan, R.O.C.
Peiwen YuOBI Pharma, Inc., Taipei, Taiwan, R.O.C.
Chuan-Fa ChangDepartment of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.ORCID http://orcid.org/0000-0003-2404-1248
Leo Pharma (Australia) · AUNational Cheng Kung University · TWKaohsiung Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycosylation is a protein post translational modification which plays important role in protein function, stabilization, trafficking, and turnover. Alteration of protein glycosylation is a common phenomenon during tumor progression, migration, invasion, angiogenesis, as well as metastasis. Hence, aberrant glycan structures and the induced corresponding anti-carbohydrate antibodies are potential biomarkers for cancer diagnosis. In this study, serum N-glycomes and anti-carbohydrate antibodies from normal populations and oral squamous cell carcinoma (OSCC) patients were investigated. Total serum proteins were lyophilized and subjected to chemical reduction, alkylation and trypsin digestion. The N-glycans were released, purified, permethylated, and analyzed using MALDI-TOF-Mass spectrometry. In addition, the serum anti-carbohydrate antibody profiles were also investigated by carbohydrate microarray. We found that the relative abundances of seven N-glycans were decreased or increased in serum of OSCC with diagnostic accuracy greater than 75%. The relative abundances of total tri-antennary and tetra-antennary glycans with varying degrees of fucosylation and sialylation were also increased in serum N-glycomes of OSCC. In an independent validation group of forty-eight OCCC patients, most of the high-molecular weight serum N-glycans showed significantly high sensitivity and specificity according to the identified cutoff values. Furthermore, the serum levels of two IgM antibodies were elevated accompanied with the decreased levels of nine IgG antibodies in patient serum. Taken together, these serum N-glycans and antibodies identified in this study should be considered as the candidates of potential biomarkers for OSCC diagnosis.

Indexed as

AntibodiesBiomarkersCarbohydratesCarcinoma, Squamous CellGlycoproteinsHumansImmunoglobulin GImmunoglobulin MMouth NeoplasmsPolysaccharidesSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAntibodiesBiomarkersCarbohydratesGlycoproteinsImmunoglobulin GImmunoglobulin MPolysaccharides

Identifiers

PMID28594851
PMCPMC5464575
OpenAlexW2623759186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.